Form 4: Aptevo Therapeutics Executive VP Lamothe Reports Stock Transactions
SEC Form 4
Jeffrey G. Lamothe, EVP and COO of Aptevo Therapeutics, reports the vesting of restricted stock units into common stock on March 2nd and 3rd, 2025.
Summary
- Jeffrey G. Lamothe, an Executive Vice President and COO at Aptevo Therapeutics Inc., filed a Form 4.
- The form details the vesting of restricted stock units (RSUs) into common stock.
- On March 2, 2025, 34 shares of common stock were acquired through the vesting of RSUs.
- On March 3, 2025, 36 shares of common stock were acquired through the vesting of RSUs.
- The RSUs convert into common stock on a one-for-one basis.
- The reporting person now directly owns 34 and 36 shares of common stock respectively.
- The RSUs were granted on March 3, 2023 (16,500 RSUs) and June 7, 2022 (11,000 RSUs) and vest in three approximately equal annual installments.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to executive compensation. It doesn't indicate positive or negative sentiment, but rather a standard process.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The vesting of RSUs has a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 2022-06-07 | Reporting person was granted 11,000 (7 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023. |
| 2023-03-03 | Reporting person was granted 16,500 (11 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024. |
| 2025-03-02 | Transaction date: Vesting of RSUs into 34 shares of common stock. |
| 2025-03-03 | Transaction date: Vesting of RSUs into 36 shares of common stock. |
| 2025-03-04 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.